Single Source Competition for Continuation of Understanding and Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)
Forecast
National Institutes of Health plans to offer grants to the applicants described in the notice. It expects to make one award worth $35.0 million in total. It is a forecast: the notice is expected around February 2, 2027, with applications due around March 10, 2027.
From the official notice on Grants.gov, last changed August 4, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awards1
- Total funding$35.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Forecast posted | August 4, 2026 |
|---|---|
| Expected posting | February 2, 2027 |
| Expected deadline | March 10, 2027 |
| Expected award date | November 1, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
This is a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The DISCOVERY of Risk Factors for Type 2 Diabetes in Youth Study is a multi-center longitudinal consortium conducted across 19 clinical sites to identify risk factors and biological mechanisms driving progression to youth-onset type 2 diabetes. The study is actively recruiting and following early pubertal youth at high risk for the disease with longitudinal follow-up currently underway. The current Biostatistics Research Center (BRC) serves as the consortium's central coordinating center, managing protocol implementation, data management, quality assurance, statistical design and analysis, and inter-site and consortium-wide coordination. The BRC has established the robust infrastructure and standardized processes required to support the study and preserve the integrity of the longitudinal dataset. The purpose of this single-source solicitation is to support completion of the scientific objectives of the ongoing DISCOVERY clinical consortium.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK_DEM@nih.gov, NIDDK_DEM@nih.gov.
Questions people ask
Who can apply for Single Source Competition for Continuation of Understanding and Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepts applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Single Source Competition for Continuation of Understanding and Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)?
Expected deadline March 10, 2027. Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
About $35.0 million in total for one award.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience